Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3754370 | 0.89 | MAPK14 (0.57) | NPC1RAB9ACYP2C9MAPK14SMYD3 | |
| SCHEMBL24553265 | 0.87 | GLA (0.56) | NPC1RAB9ACYP3A4CYP2C9MAPK14 | |
| SCHEMBL7880726 | 0.86 | HTR1D (0.54) | NPC1RAB9ADRD4CNR2HPGD | |
| SCHEMBL30356809 | 0.86 | SMYD3 (0.47) | SMYD3DRD4HPGDSLC6A5HDAC4 | |
| SCHEMBL31495203 | 0.86 | HTR1D (0.54) | NPC1RAB9ADRD4CNR2HPGD | |
| SCHEMBL13363749 | 0.86 | SMYD3 (0.47) | SMYD3DRD4HPGDSLC6A5HDAC4 | |
| SCHEMBL28079514 | 0.86 | RAB9A (0.60) | NPC1RAB9ACYP3A4CYP2C9CNR2 | |
| SCHEMBL13575587 | 0.86 | NPC1 (0.54) | NPC1RAB9AMAPK14DRD4SLC6A5 | |
| SCHEMBL1559555 | 0.85 | KMT2A (0.49) | SMYD3CNR2SLC6A5 | |
| SCHEMBL3543621 | 0.85 | HDAC6 (0.52) | SMYD3HPGDSLC6A5HDAC4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50082-E1 | (5,6-dihydro)pyrimido[4,5-e]indolizines | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2024-08-20 | — | — | US | disclosed |
| CN-106132963-B | (5, 6-dihydro) pyrimido [4,5-e ] indolizines | 荷兰转化研究中心有限责任公司 | 2019-08-06 | — | — | CN | disclosed |
| EP-3129374-B1 | (5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOLIZINES | NETHERLANDS TRANSLATIONAL RES CENTER B V (NL) | 2018-12-19 | — | — | EP | disclosed |
| US-9856258-B2 | (5,6-dihydro)pyrimido[4,5-E]indolizines | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2018-01-02 | — | — | US | disclosed |
| US-20170096432-A1 | (5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOLIZINES | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2017-04-06 | — | — | US | disclosed |
| CN-106132963-A | (5, 6-dihydro) pyrimido [4,5-e ] indolizines | 荷兰转化研究中心有限责任公司 | 2016-11-16 | — | — | CN | disclosed |
| EP-2564850-A1 | Polo-like kinase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| WO-2009153197-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009112524-A1 | PYRIDOPYRIMIDINES AS PLK1 ( POLO-LIKE KINASE) INHIBITORS | 4SC AG (DE) | 2009-09-17 | — | — | WO | disclosed |
| EP-2100894-A1 | Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors | 4SC AG (DE) | 2009-09-16 | — | — | EP | disclosed |
| CN-101511836-A | Fused pyrimido compounds | ASTRAZENECA AB (SE) | 2009-08-19 | — | — | CN | disclosed |
| EP-2046793-A2 | FUSED PYRIMIDO COMPOUNDS | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| WO-2009042711-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-02 | — | — | WO | disclosed |
| WO-2008113711-A1 | SUBSTITUTED PYRIMIDODIAZEPINES USEFUL AS PLK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008040951-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096432-A1 | (5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOLIZINES | DHFR, CYP2D6, DPYD | NPC1 1874/4885RAB9A 539/4885CYP3A4 23/4885 |
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | NPC1 13/4885RAB9A 1172/4885CYP3A4 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.